Efficacy News and Research

RSS

Breakthrough in pancreatic cancer treatment

Epeius Biotechnologies (www.epeiusbiotech.com) confirms the first real breakthrough for pancreatic cancer seen in years; publishes a landmark report of tumor-targeted Rexin-G as stand-alone therapy in chemotherapy-resistant pancreatic cancer.

14 Oct 2009

Older generation antibiotic for treating colon cancer

A new Tel Aviv University drug, based on an older generation antibiotic, may provide doctors with an effective and innovative method of treating colon cancer in both its incipient and full-blown stages ― and minimize the need for painful, uncomfortable colonoscopies and surgical polyp removal.

14 Oct 2009

New neurosurgical procedure may prove helpful for patients with treatment-resistant depression

A new neurosurgical procedure may prove helpful for patients with treatment-resistant depression. Bilateral epidural prefrontal cortical stimulation (EpCS) was found generally safe and provided significant improvement of depressive symptoms in a small group of patients, according to lead researcher Ziad Nahas, M.D. at the Medical University of South Carolina. The data are reported in the on-line issue of Biological Psychiatry.

14 Oct 2009

Researchers to investigate an existing drug for speedy recovery of stroke patients

New research will determine whether an inexpensive drug called L-dopa, widely used in the treatment of Parkinson's disease, could also help thousands of stroke patients regain mobility and independence.

14 Oct 2009

Decision Resources: Rheumatoid arthritis drug market in India to grow up to $672 million in 2013

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the rheumatoid arthritis drug market in India will more than double by 2013, growing from $296 million in 2008 to $672 million in 2013.

14 Oct 2009

Epeius Biotechnologies announces clinical study results of tumor-targeted genetic medicine

Epeius Biotechnologies Corporation today announced more stunning results of its pioneering clinical studies of Rexin-G, the world's first and, so far only, tumor-targeted genetic medicine to be validated in the clinic.

14 Oct 2009

AVANIR Pharmaceuticals announces results of Zenvia double-blind Phase III STAR trial

AVANIR Pharmaceuticals, Inc. today announced detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS).

14 Oct 2009

Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

Provectus Pharmaceuticals, Inc., a development stage oncology and dermatology biopharmaceutical company, has completed patient accrual and initial treatment in its Phase 2 trial of PH-10 for the treatment of plaque psoriasis. This milestone marks the third Phase 2 clinical trial for which Provectus has completed patient accrual since May 2009.

13 Oct 2009

Onyx Pharmaceuticals signs definitive agreement to acquire Proteolix

Proteolix, Inc. today announced that it has signed a definitive agreement to be acquired by Onyx Pharmaceuticals, Inc.

13 Oct 2009

Merck Frosst Canada's JANUMET receives Notice of Compliance in Canada

Merck Frosst Canada Ltd. announced today that its new diabetes treatment, JANUMET(TM) (sitagliptin/metformin HCI, MSD), has received Notice of Compliance (NoC) in Canada.

13 Oct 2009

$SAFC Pharma's Pharmorphix Solid State Research Laboratories installs new single crystal X-ray diffraction system$

SAFC Pharma's Pharmorphix Solid State Research Laboratories installs new single crystal X-ray diffraction system

SAFC Pharma®, a business segment of SAFC®, a member of the Sigma-Aldrich® Group, today announced that its Pharmorphix® Solid State Research Laboratories in Cambridge, UK, have installed a new single crystal X-ray diffraction system. The Oxford Diffraction SuperNova(TM) system, which can determine the crystal structures from the most challenging crystal samples, is the first industrial installation of this state-of-the-art instrumentation anywhere in the world.

13 Oct 2009

Debiopharm Group and Ipsen complete European decentralised registration of Decapeptyl

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical Group, announced that the 6-month sustained-release formulation of Decapeptyl®1 (triptorelin embonate2 22.5 mg) successfully completed its European decentralised registration procedure involving nine countries: Germany (reference member state), France, Austria, Finland, Norway, Belgium, Denmark, Spain and The Netherlands.

13 Oct 2009

WellPoint honored for its "Journey Forward" initiative

WellPoint, Inc. was recognized today as a 2009 BlueWorks® award winner. BlueWorks is a unique partnership between the Blue Cross and Blue Shield Association (BCBSA) and the Harvard Medical School Department of Health Care Policy that honors health care innovation that improves the quality and value of health care for consumers.

12 Oct 2009

NDS Surgical Imaging to demonstrate ConnectOR G2 medical-grade appliance for operating theaters

NDS Surgical Imaging (NDSsi) announced the preview of the next generation informatics appliance for the minimally invasive surgical suite – ConnectORTMG2.

12 Oct 2009

Z-Medica launches QuikClot Trauma Pad

Z-Medica Corporation, a medical device company developing innovative hemostatic agents, today announced the availability of the QuikClot® Trauma Pad™ hemostatic dressing, on display at booth #1721 at the American College of Surgeons 95th Annual Clinical Congress. The new QuikClot Trauma Pad’s 12 x 12 inch size makes it well-suited to control bleeding from large traumatic wounds.

From Medica Corporation 12 Oct 2009

Arena Pharmaceuticals to present Phase 3 BLOSSOM trial results at Obesity 2009

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that lorcaserin will be featured in multiple presentations at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society in Washington, DC.

12 Oct 2009

FDA grants marketing approval for CSL Behring's Berinert C1-Esterase Inhibitor

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Berinert® C1-Esterase Inhibitor, Human for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE), a rare and serious genetic disorder, in adult and adolescent patients. Berinert is the first and only therapy approved for this indication in the U.S.

12 Oct 2009

ImmuneRegen BioSciences to test efficacy of Homspera against H5N1 Avian Influenza

ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.

12 Oct 2009

Depomed announces results from BREEZE 1 and 2 Phase 3 clinical trials of Serada

Depomed, Inc. announced today top-line results from the BREEZE 1 and 2 Phase 3 clinical trials evaluating the safety and efficacy of SeradaTM, an investigational non-hormonal extended release formulation of gabapentin for the treatment of menopausal hot flashes.

12 Oct 2009

Results of Phase 2a clinical trial of DR Cysteamine announced by Raptor Pharmaceutical

Raptor Pharmaceutical Corp., announced positive findings from the completed treatment phase of its open-label Phase 2a clinical trial of delayed-release cysteamine bitartrate ("DR Cysteamine") in adolescent patients with non-alcoholic steatohepatitis ("NASH"), a progressive form of liver disease believed to affect 2% to 5% of the U.S. population.

12 Oct 2009

Efficacy News and Research

Breakthrough in pancreatic cancer treatment

Older generation antibiotic for treating colon cancer

New neurosurgical procedure may prove helpful for patients with treatment-resistant depression

Researchers to investigate an existing drug for speedy recovery of stroke patients

Decision Resources: Rheumatoid arthritis drug market in India to grow up to $672 million in 2013

Epeius Biotechnologies announces clinical study results of tumor-targeted genetic medicine

AVANIR Pharmaceuticals announces results of Zenvia double-blind Phase III STAR trial

Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

Onyx Pharmaceuticals signs definitive agreement to acquire Proteolix

Merck Frosst Canada's JANUMET receives Notice of Compliance in Canada

SAFC Pharma's Pharmorphix Solid State Research Laboratories installs new single crystal X-ray diffraction system

Debiopharm Group and Ipsen complete European decentralised registration of Decapeptyl

WellPoint honored for its "Journey Forward" initiative

NDS Surgical Imaging to demonstrate ConnectOR G2 medical-grade appliance for operating theaters

Z-Medica launches QuikClot Trauma Pad

Arena Pharmaceuticals to present Phase 3 BLOSSOM trial results at Obesity 2009

FDA grants marketing approval for CSL Behring's Berinert C1-Esterase Inhibitor

ImmuneRegen BioSciences to test efficacy of Homspera against H5N1 Avian Influenza

Depomed announces results from BREEZE 1 and 2 Phase 3 clinical trials of Serada

Results of Phase 2a clinical trial of DR Cysteamine announced by Raptor Pharmaceutical

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News